Sanofi to acquire Principia Biopharma in $3.68bn deal
Principia Biopharma is a late-stage biopharmaceutical company that develops transformative therapies for immune-mediated diseases
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 Aug 20
Principia Biopharma is a late-stage biopharmaceutical company that develops transformative therapies for immune-mediated diseases
11 Aug 20
Ligand will pay $2 per share, valuing a total of $78m as a Contingent Value Right (CVR) in…
23 Jul 20
The US government will pay $1.95bn, after receiving of the 100 million doses, and has an option to…
17 Jul 20
The revised bid has raised the initial offer price of €39.00 per share to a new price of…
26 May 20
The acquisition will allow Roche to access Stratos Genomics’ advanced Sequencing by Expansion (SBX) chemistry, and complement the…
12 May 20
Thermo Fisher’s $180m expansion project would increase its commercial viral vector capacity by more than double and support…
07 Apr 20
The clinical study is aimed at evaluating efficacy and safety of Hope’s autologous, adipose-derived mesenchymal stem cells (HB-adMSCs)
07 Apr 20
Both GSK, Vir Biotechnology will apply their combined expertise to research on vaccines for SARS-CoV-2 and other coronaviruses
26 Mar 20
Early data generated using Thermo Fisher’s new NGS research panel suggest coronavirus is genetically stable
Moderna has already given a dose of its potential Covid-19 vaccine to a patient